Sugi Predict

Sugi Predict / Compounds / SCHEMBL906352

SCHEMBL906352

SCHEMBL906352

COC(=O)c1ccc(NC(=O)N2CCN(c3ncnc4cc(OCCCN5CCCC5)c(OC)cc34)CC2)cc1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDGFRB P09619 20/20 0.80
▸ KIT P10721 5/20 0.78
▸ FLT3 P36888 5/20 0.78
▸ CSF1R P07333 3/20 0.78
▸ PLK4 O00444 1/20 0.78
▸ GAK O14976 1/20 0.78
▸ EPHB6 O15197 1/20 0.78
▸ STK10 O94804 1/20 0.78
▸ EGFR P00533 1/20 0.78
▸ NTRK1 P04629 1/20 0.78
▸ LCK P06239 1/20 0.78
▸ FGFR1 P11362 1/20 0.78
▸ SRC P12931 1/20 0.78
▸ PDGFRA P16234 1/20 0.78
▸ FLT1 P17948 1/20 0.78
▸ FGFR2 P21802 1/20 0.78
▸ FGFR4 P22455 1/20 0.78
▸ FGFR3 P22607 1/20 0.78
▸ AXL P30530 1/20 0.78
▸ FLT4 P35916 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL906260 0.94 PDGFRB (0.80) PDGFRBKITFLT3CSF1RPLK4
SCHEMBL906259 0.94 PDGFRB (0.80) PDGFRBKITFLT3CSF1RPLK4
SCHEMBL13330543 0.92 PDGFRB (0.83) PDGFRBKITFLT3CSF1RPLK4
SCHEMBL906256 0.91 PDGFRB (0.81) PDGFRBKITFLT3CSF1RPLK4
SCHEMBL13355149 0.91 PDGFRB (0.83) PDGFRBKITFLT3CSF1RPLK4
SCHEMBL13168045 0.91 PDGFRB (0.83) PDGFRBKITFLT3CSF1RPLK4
SCHEMBL3315768 0.91 PDGFRB (0.81) PDGFRBKITFLT3CSF1RPLK4
SCHEMBL13330531 0.89 PDGFRB (0.80) PDGFRBKITFLT3CSF1RPLK4
SCHEMBL13330529 0.89 PDGFRB (0.78) PDGFRBKITFLT3CSF1RPLK4
SCHEMBL12694513 0.89 PDGFRB (0.83) PDGFRBKITFLT3CSF1RPLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150133439-A1 QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. 2015-05-14 — — US claimed
US-20130274252-A1 QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. 2013-10-17 — — US claimed
EP-1315715-A1 QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS Millennium Pharmaceuticals, Inc. (US) 2003-06-04 — — EP claimed
WO-2002016351-A1 QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS COR THERAPEUTICS, INC. (US) 2002-02-28 — — WO claimed
US-20150133439-A1 QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. 2015-05-14 — — US disclosed
US-20150133439-A1 QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. 2015-05-14 — — US disclosed
US-20130274252-A1 QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. 2013-10-17 — — US disclosed
US-20130274252-A1 QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. 2013-10-17 — — US disclosed
US-8324205-B2 Quinazoline derivatives as kinase inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-12-04 — — US disclosed
US-8324205-B2 Quinazoline derivatives as kinase inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-12-04 — — US disclosed
US-8324205-B2 Quinazoline derivatives as kinase inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-12-04 — — US disclosed
EP-2277877-A1 Quinazoline derivatives as kinase inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-26 — — EP disclosed
US-20090136450-A1 THERAPY FOR NEUROLOGICAL DISEASES ARES TRADING S.A. (CH) 2009-05-28 — — US disclosed
EP-1964839-A2 Quinazoline derivatives as kinase inhibitors Millennium Pharmaceuticals, Inc. (US) 2008-09-03 — — EP disclosed
EP-1964839-A2 Quinazoline derivatives as kinase inhibitors Millennium Pharmaceuticals, Inc. (US) 2008-09-03 — — EP disclosed
US-6982266-B2 N-(4-indol-5-yloxyphenyl){4-[6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yl]piperazinyl}carboxamide for example; antiproliferative agents which inhibit phosphorylation of kinases such as tyrosine kinase; cancer, arteriosclerosis MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-01-03 — — US disclosed
US-20050288297-A1 Quinazoline derivatives as kinase inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-12-29 — — US disclosed
US-20050101609-A1 Quinazoline derivatives as kinase inhibitors KYOWA HAKKO KOGYO CO, LTD. (JP) 2005-05-12 — — US disclosed
EP-1315715-A1 QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS Millennium Pharmaceuticals, Inc. (US) 2003-06-04 — — EP disclosed
WO-2002016351-A1 QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS COR THERAPEUTICS, INC. (US) 2002-02-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150133439-A1 QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS WNK2, WNK1, WNK3 PDGFRB 10/4885KIT 495/4885FLT3 217/4885
US-20130274252-A1 QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS WNK2, WNK1, WNK3 PDGFRB 10/4885KIT 495/4885FLT3 217/4885
US-20050101609-A1 Quinazoline derivatives as kinase inhibitors TNNI3K, PDGFRA, TEK PDGFRB 4/4885KIT 122/4885FLT3 244/4885
US-20050288297-A1 Quinazoline derivatives as kinase inhibitors WNK2, WNK1, WNK3 PDGFRB 10/4885KIT 495/4885FLT3 217/4885
US-20090136450-A1 THERAPY FOR NEUROLOGICAL DISEASES KIT, NGF, PMP22 PDGFRB 191/4885KIT 1/4885FLT3 344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.